

## **AGENDA**

### **High-Risk NMIBC**

May 20, 2021

5 PM ET



**LUGPA**  
Integrated Practices  
Comprehensive Care

#### Introduction

**Neal Shore, MD and Larry Karsh, MD**

3 minutes

#### The Role of Nadofaragene Firadenovec in the Treatment of NMIBC

**Colin Dinney MD**

10 minutes

#### The Role of Blue Light Cystoscopy in Detecting Invasive Bladder Tumors

**Siamak Daneshmand, MD**

10 minutes

#### The Role of Pembrolizumab in the Treatment of NMIBC

**Ashish Kamat, MD**

10 minutes

#### The Evaluation of Cxbladder and Adjudication of Atypical Cytology

**Sima Porten, MD**

10 minutes

#### Durvalumab and BCG versus BCG Alone in High-risk, BCG-Naïve Non-Muscle Invasive Bladder Cancer

**Maria de Santis, MD**

10 minutes

#### The Role of Vicinium in Treatment of NMIBC

**Wassim Kassouf, MD**

10 minutes

#### Conclusion

**Neal Shore, MD and Larry Karsh, MD**

2 minutes

***This event will be followed immediately by a NMIBC product theater presented by Merck.***

#### **Description:**

Currently, there are a variety of management options for both BCG naïve and BCG unresponsive high risk NMIBC. Although radical cystectomy (RC) is recommended for many patients with high risk BCG unresponsive disease, many patients decline to undergo or are ineligible to proceed with RC. Patients and physicians seek efficacious and safe therapeutic options as alternatives to RC. This program will address educational concerns by improving awareness and knowledge of therapeutic options for patients high-risk NMIBC patients as well as an understanding of both novel mechanisms of action and differences in both administration and adverse event profile management .

#### **Desired outcome:**

As a result of this program physicians will examine and identify the risks and benefits of multiple therapeutic options for patients with non-muscle invasive bladder cancer (NMIBC)

**Learning Objectives:**

- At the conclusion of this activity participants will be able to:
- Examine multiple therapeutic options for patients with non-muscle invasive bladder cancer (NMIBC)
- Determine the risks and benefits of various treatment options for high risk NMIBC patients
- Identify options to detect and treat patients with high-risk NMIBC

**References:**

Chang SS, Boorjian SA, Chou R et al: Diagnosis and treatment of non-muscle invasive bladder cancer: [AUA/SUO guideline. J Urol. 2016; 196: 1021.](#)

Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer

Maxwell V. Meng, Jürgen E. Gschwend, Neal Shore, Gary D. Grossfeld, Hugh Mostafid, and Peter C. Black.

<https://doi.org/10.1097/JU.0000000000000297>